Louis Garguilo


  • 8/19/2022

    Lyndra Therapeutics is designing in-house a specialized, continuous and automated manufacturing line to manufacture its new long-acting oral-drug products. Someday, it hopes to export that line to partners around the world. The strategy starts with a basic scientific knowledge that propels an organization to continuous.”

  • 8/15/2022

    A miniature manmade “star” – with round middle and triangular arms – collapses to fit into a capsule and provides patients an oral drug. The creators of this device-like drug are devoted to manufacturing through continuous manufacturing. Can the company also outsource some of what they've developed internally?

  • 8/10/2022

    There's a hiring crunch out there, and today drug sponsors are recruiting from inside some of their CDMOs. Is that a good strategy? We'll take a look at both sides of the equation.

  • 8/3/2022

    Steve Goodman, Vertex Pharmaceuticals has been outsourcing development and manufacturing for years. “I’ve been successful because my approach to managing a CDMO is mostly agnostic to modality,” he says. Here are a few more of his best practices.

  • 7/27/2022

    Steve Goodman’s new title at Vertex Pharmaceuticals catches the eye: Executive Director, AAV Process Development and Manufacturing. It points us to where our industry is rapidly heading. In fact, we might say Goodman himself has been a leading indicator. 

  • 7/20/2022

    I first described Cosette Pharmaceuticals as an “innovative specialty generics” organization, but President & CEO Apurva Saraf had us questioning all three of those words, and how we use them (or shouldn't) today.

  • 7/13/2022

    “I have not wanted to go to India or China for most of my API needs, and to the extent possible I do not want to go there for formulations either,” is part of a surprising sentiment from a long-tenured generics outsourcing professional.  

  • 7/11/2022

    When it reaches criticality at your CDMO – like the potential delivery delay of clinical material – it’s "Hypercare" time. That’s the word coined at Alexion Therapeutics for an intensified coordination and managing of activities at CDMOs in crucial moments. Read on: Hypercare might be right for you, too.

  • 7/1/2022

    Have you sufficiently examined the “life” of your drug development and manufacturing outsourcing? If you rely on outsourcing as an external life force to get you into and through the clinic (and perhaps beyond), how you answer that has never been more important.

  • 6/21/2022

    We the People of the Outsourcing Industry, in Order to form a more perfect Union, establish Service, ensure Reliability, and secure the Blessings of our system of drug development and manufacturing, establish this Constitution for working with CDMOs. (Preamble to the Outsourcing Constitution)


Louis Garguilo

Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.